|
[1]Tak P, Kate F.Remission of active diabetic hepatitis after correc-tion of hyperglycemia[J].Liver, 1993, 13 (4) :183.
|
|
[2]Park SH, Kim DJ, Lee HY.Insulin resistance is not associated withhistologic severity in nondiabetic, noncirrhotic patients with chronichepatitis B virus infection[J].Am J Gastroenterol, 2009, 104 (5) :1135-1139.
|
|
[3]Nakai T, Tanimura H, Hirokawa F, et al.Altered hepatic hemody-namics and improved liver function following in trahepatic vascularinfusion of prostag land in E1[J].J Gastroenterol, 1998, 33 (3) :362-367.
|
|
[4]Zhang WW, Wang XQ, Li Y.Insulin resistance and serum growthhormone level in patients with cirrhosis[J].World Chin J Dig, 2002, 10 (10) :1180-1183. (in Chinese) 张卫卫, 王学清, 李岩.肝硬化胰岛素抵抗及血清生长激素水平的研究[J].世界华人消化杂志, 2002, 10 (10) :1180-1183.
|
|
[5]Chinese Society of Infectious Diseases and Parasitology and ChineseSociety of Hepatology of Chinese Medical Association.Preventionand treatment of viral hepatitis[J].Chin J Hepatol, 2000, 8 (6) :324-329. (in Chinese) 中华医学会传染病与寄生虫病学分会, 肝病学分会.病毒性肝炎防治方案[J].中华肝脏病杂志, 2000, 8 (6) :324-329.
|
|
[6]Han YH, Li ST.Clinical Hepatology[M].Jinan:Shandong Sci-ence and Technology Press, 2004:6. (in Chinese) 韩硬海, 李树桐.临床肝脏病学[M].济南:山东医学技术出版社, 2004:6.
|
|
[7]Edvardsson U, von Lwenhielm HB, Panfilov O, et al.Hepaticprotein expression of lean mice and obese diabetic mice treated withperoxisome proliferator-activated receptor activators[J].Pro-teomics, 2003, 3 (4) :468-478.
|
|
[8]Zhao JJ, Zhang ZF.Therapeutic efficacy of adefovir dipivoxil intreatment of hepatitis B cirrhosis with hepatogenous diabetes[J].JClin Hepatol, 2009, 25 (1) :46-47. (in Chinese) 赵建军, 张志峰.阿德福韦酯治疗乙型肝炎肝硬化伴肝源性糖尿病的疗效观察[J].临床肝胆病杂志, 2009, 25 (1) :46-47.
|
|
[9]Wang HN, Wen WB.Progress in clinical research on hepatogenousdiabetes[J].J Clin Hepatol, 2003, 6 (1) :59-60. (in Chinese) 王华宁, 温伟波.肝源性糖尿病临床研究进展[J].实用肝脏病杂志, 2003, 6 (1) :59-60.
|
|
[10]Han HM.Current situation of research on pathogenesis of hepatoge-nous diabetes[J].J Clin Hepatol, 2006, 22 (2) :152-153. (inChinese) 韩红梅.肝源性糖尿病发病机制的研究现状[J].临床肝胆病杂志, 2006, 22 (2) :152-153.
|
|
[11]YU MX, Yin HM, Li YJ, et al.The treatment status of hepatoge-nous diabetes[J].J Clin Hepatol, 2011, 27 (7) :779-782. (inChinese) 于明霞, 尹威民, 李迎今, 等.肝源性糖尿病的治疗现状[J].临床肝胆病杂志, 2011, 27 (7) :779-782.
|
|
[12]Gao AH, Wang XL, Jiang QH, et al.Clinical observation on influ-ence of livweiwuling tablets combined with entecavir on chronic hep-atitis B patients with HBeAg positive[J].Chin J Liver Dis (Elec-tren Vers) , 2011, 3 (1) :35-37. (in Chinese) 高爱华, 王新丽, 姜清河, 等.六味五灵片联合恩替卡韦治疗HBeAg阳性慢性乙型肝炎患者的疗效观察[J].中国肝脏病杂志 (电子版) , 2011, 3 (1) :35-37.
|
|
[13]Li L, Cheng J, Ji D.Research progress in treatment of hepatogenousdiabetes[J].World Chin J Dig, 2004, 12 (7) :1659-1662. (inChinese) 李莉, 成军, 纪冬.肝源性糖尿病的治疗研究进展[J].世界华人消化杂志, 2004, 12 (7) :1659-1662.
|
DownLoad: